Abstract
Introduction Head and neck squamous cell carcinoma (HNSCC), which includes cancers of the oral cavity and oropharynx, is a cause of substantial global morbidity and mortality. Strategies to reduce disease burden include discovery of novel therapies and repurposing of existing drugs. Statins are commonly prescribed for lowering circulating cholesterol by inhibiting HMG-CoA reductase (HMGCR). Results from some observational studies suggest that statin use may reduce HNSCC risk. We appraised the relationship of genetically-proxied cholesterol-lowering drug targets and other circulating lipid traits with oral (OC) and oropharyngeal (OPC) cancer risk.
Methods and findings We conducted two-sample Mendelian randomization (MR). For the primary analysis, germline genetic variants in HMGCR, NPC1L1, CETP, PCSK9 and LDLR were used to proxy the effect of low-density lipoprotein cholesterol (LDL-C) lowering therapies. In secondary analyses, variants were used to proxy circulating levels of other lipid traits in a genome-wide association study (GWAS) meta-analysis of 188,578 individuals. Both primary and secondary analyses aimed to estimate the downstream causal effect of cholesterol lowering therapies on OC and OPC risk.
The second sample for MR was taken from a GWAS of 6,034 OC and OPC cases and 6,585 controls (GAME-ON). Analyses were replicated in UK Biobank, using 839 OC and OPC cases and 372,016 controls and the results of the GAME-ON and UK Biobank analyses combined in a fixed-effects meta-analysis.
We found limited evidence of a causal effect of genetically-proxied LDL-C lowering using HMGCR, NPC1L1, CETP or other circulating lipid traits on either OC or OPC risk. Genetically-proxied PCSK9 inhibition equivalent to a 1 mmol/L (38.7 mg/dL) reduction in LDL-C was associated with an increased risk of OC and OPC combined (OR 1.8 95%CI 1.2, 2.8, p= 9.31 ×10−05), with good concordance between GAME-ON and UK Biobank (I2= 22%). Effects for PCSK9 appeared stronger in relation to OPC (OR 2.6 95%CI 1.4, 4.9) than OC (OR 1.4 95%CI 0.8, 2.4). LDLR variants, resulting in genetically-proxied reduction in LDL-C equivalent to a 1 mmol/L (38.7 mg/dL), reduced the risk of OC and OPC combined (OR 0.7, 95%CI 0.5, 1.0, p= 0.006). A series of pleiotropy-robust and outlier detection methods showed that pleiotropy did not bias our findings.
Conclusion We found limited evidence for a role of cholesterol-lowering in OC and OPC risk, suggesting previous observational results may have been confounded. There was some evidence that genetically-proxied inhibition of PCSK9 increased risk, while lipid-lowering variants in LDLR, reduced risk of combined OC and OPC. This result suggests that the mechanisms of action of PCSK9 on OC and OPC risk may be independent of its cholesterol lowering effects, but further replication of this finding is required.
Why was this study done?
To determine if genetically-proxied cholesterol-lowering drugs (such as statins which target HMGCR) reduce oral and oropharyngeal cancer risk.
To determine if genetically-proxied circulating lipid traits (e.g. low-density lipoprotein cholesterol) have a causal effect on oral and oropharyngeal cancer risk.
What did the researchers do and find?
There was little evidence that genetically-proxied inhibition of HMGCR (target of statins), NPC1L1 (target of ezetimibe) and CETP (target of CETP inhibitors) influences oral or oropharyngeal cancer risk.
There was little evidence of an effect of circulating lipid traits on oral or oropharyngeal cancer risk.
There was some evidence that genetically-proxied inhibition of PCSK9 increases, while lipid-lowering variants in LDLR reduces oral and oropharyngeal cancer risk.
What do these findings mean?
These findings suggest that the results of previous observational studies examining the effect of statins on oral and oropharyngeal risk may have been confounded.
Given we found little evidence of an effect of other cholesterol lowering therapies, the mechanism of action of PCSK9 may be independent of cholesterol-lowering. Further replication of this finding in other head and neck cancer datasets is required.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
M.G. was a National Institute for Health Research (NIHR) academic clinical fellow and is currently supported by a Wellcome Trust GW4-Clinical Academic Training PhD Fellowship. This research was funded in part, by the Wellcome Trust [Grant number 220530/Z/20/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. R.C.R. is a de Pass VC research fellow at the University of Bristol. J.T. is supported by an Academy of Medical Sciences (AMS) Springboard award, which is supported by the AMS, the Wellcome Trust, Global Challenges Research Fund (GCRF), the Government Department of Business, Energy and Industrial strategy, the British Heart Foundation and Diabetes UK (SBF004\1079). R.M.M. was supported by a Cancer Research UK (C18281/A19169) programme grant (the Integrative Cancer Epidemiology Programme) and is part of the Medical Research Council Integrative Epidemiology Unit at the University of Bristol supported by the Medical Research Council (MC_UU_12013/1, MC_UU_12013/2, and MC_UU_12013/3) and the University of Bristol. JY is supported by a Cancer Research UK Population Research Postdoctoral Fellowship (C68933/A28534). R.M.M. and A.R.N. are supported by the National Institute for Health Research (NIHR) Bristol Biomedical Research Centre which is funded by the National Institute for Health Research (NIHR) and is a partnership between University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. This publication presents data from the Head and Neck 5000 study. The study was a component of independent research funded by the NIHR under its Programme Grants for Applied Research scheme (RP-PG-0707-10034). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Core funding was also provided through awards from Above and Beyond, University Hospitals Bristol Research Capability Funding and the NIHR Senior Investigator award to A.R.N. Human papillomavirus (HPV) serology was supported by a Cancer Research UK Programme Grant, the Integrative Cancer Epidemiology Programme (grant number: C18281/A19169). B.D. and the University of Pittsburgh head and neck cancer case-control study are supported by US National Institutes of Health (NIH) grants: P50 CA097190, P30 CA047904 and R01 DE025712. The genotyping of the HNSCC cases and controls was performed at the Center for Inherited Disease Research (CIDR) and funded by the US National Institute of Dental and Craniofacial Research (NIDCR; 1X01HG007780-0). The University of North Caroline (UNC) CHANCE study was supported in part by the National Cancer Institute (R01-CA90731). E.E.V and D.L are supported by Diabetes UK (17/0005587). E.E.V is also supported by the World Cancer Research Fund (WCRF UK), as part of the World Cancer Research Fund International grant programme (IIG_2019_2009). E.H.T and P.S. were supported by the GENCAPO/FAPESP grant (10/51168-0).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project was undertaken as part of a Wellcome Trust PhD fellowship. UK Biobank approval was given for this project (ID 40644- Investigating aetiology, associations and causality in diseases of the head and neck) and UK Biobank GWAS data was also accessed under the application (ID 15825- MR-Base: an online resource for Mendelian randomization using summary data- Dr. Philip Haycock). No UK Biobank data was de-identified and at all times was used in accordance with their policies on data storage and management. An additional project application was approved by the Head and Neck 5000 study which is part of the Genetic Associations and Mechanisms in Oncology (GAME-ON) Network. Head and Neck 5000 already has NHS Research Ethics Committee (REC) approval in place(http://www.headandneck5000.org.uk/information-for-researchers/ongoingprojects/). Full summary statistics for the GAME-ON GWAS can be accessed via dbGAP (OncoArray: Oral and Pharynx Cancer; study accession number: phs001202.v1.p1). All genetic summary data used in the study is publicly available.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updated information on UK Biobank approval and references.
Data Availability
Summary-level analysis was conducted using publicly available GWAS data. Full summary statistics for the GAME-ON GWAS can be accessed via dbGAP (OncoArray: Oral and Pharynx Cancer; study accession number: phs001202.v1.p1) [34]. Access to UK Biobank (https://www.ukbiobank.ac.uk/) data is available to researchers through application.
Abbreviations
- HNSCC
- head and neck squamous cell carcinoma
- OC
- oral cancer
- OPC
- oropharyngeal cancer
- HPV
- human papilloma virus
- MR
- Mendelian randomization
- GWAS
- genome-wide association study
- SNP
- single nucleotide polymorphism
- PCA
- principal component analysis
- NOME
- no measurement error
- SIMEX
- simulation extrapolation
- MR-PRESSO
- Mendelian Randomization Pleiotropy RESidual Sum and Outlier
- GAME-ON
- Genetic Associations and Mechanisms in Oncology
- HMGCR
- 3-hydroxy-3-methylglutaryl-CoA reductase
- NPC1L1
- NPC1 like intracellular cholesterol transporter 1
- CETP
- cholesteryl ester transfer protein
- PCSK9
- proprotein convertase subtilisin/kexin type 9
- LDLR
- low-density lipoprotein receptor
- LDL-C
- low-density lipoprotein cholesterol
- HDL-C
- high-density lipoprotein cholesterol
- LD
- linkage disequilibrium
- OR
- odds ratio
- se
- standard error
- IVW
- inverse variance weighted
- CI
- confidence intervals
- P
- p-value.